U.K. Approves Rhythm Pharma's Imcivree For Treatment Of Obesity And Control Of Hunger

Rhythm Pharmaceuticals Inc. (RYTM) said that the Great Britain's Medicines & Healthcare Products Regulatory Agency or MHRA has granted marketing authorisation to Imcivree or setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 or PCSK1, deficiency or biallelic leptin receptor or LEPR deficiency in adults and children 6 years of age and above.

It is the first-ever authorised treatment option in Great Britain (England, Scotland and Wales) for these rare genetic diseases of obesity, the company said.

The National Institute for Health and Care Excellence or NICE is scheduled to review the dossier for Imcivree in December 2021. Guidance for coverage of Imcivree under the United Kingdom's National Health Service (NHS) is anticipated in the second quarter of 2022.

The company noted that the MHRA authorisation of Imcivree is based on results from the largest studies conducted to date in obesity due to POMC, PCSK1 or LEPR deficiency.

In two Phase 3 clinical trials, 8 of 10 patients with obesity due to POMC or PCSK1 deficiency achieved greater than 10 percent body weight loss after one year of treatment with IMCIVREE and 5 of 11 patients with obesity due to LEPR deficiency achieved greater than 10 percent body weight loss after one year of treatment with IMCIVREE.

Additionally, in both studies, significant decreases in body mass index (BMI) were demonstrated across patients who were 6 to 17 years old at baseline.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
HSBC Holdings Plc shares were gaining In London trading as well as in pre-market activity on the NYSE after the Asia-focused lender backed its positive outlook after reporting significantly higher third-quarter profit. Further, the company announced share buyback of $2 billion, which will be commenced shortly. Walmart is recalling certain Aromatherapy Room Spray due to the possible presence of a rare and dangerous bacteria that is suspected to be behind two deaths in the United States, the U.S. Consumer Product Safety Commission said. The recall involves about 3,900 bottles of Better Homes and Gardens-branded Essential Oil Infused Aromatherapy Room Spray with Gemstones in six different scents. Royal Caribbean Group's ultra-luxury brand Silversea Cruises is set to launch the world's first hybrid-powered cruise ship in the summer of 2023. This will also be the first ship with large-scale fuel cell technology to enable emission-free port operations. The fuel cells will provide 100% of power while at port.
Follow RTT